SFI
ABOS icon

Susquehanna Fundamental Investments’s Acumen Pharmaceuticals ABOS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,731
Closed -$25.3K – 1056
2024
Q4 		$25.3K Buy
+14,731
New +$35.5K ﹤0.01% 1064
2024
Q2 		$151K Hold
62,518
– – ﹤0.01% 871
2024
Q1 		$253K Buy
+62,518
New +$236K 0.01% 588

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Susquehanna Fundamental Investments's ABOS Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Acumen Pharmaceuticals (ABOS) in Q1 2025, closing a stake of 14,731 shares — an estimated $25.3K sold.

Susquehanna Fundamental Investments first reported a position in ABOS in Q1 2024 and held it in 3 quarters. The position peaked at $253K in Q1 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q1 2025.

  • Susquehanna Fundamental Investments reported no remaining Acumen Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 14,731 Acumen Pharmaceuticals shares in Q1 2025, an estimated $25.3K.
  • Susquehanna Fundamental Investments first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Acumen Pharmaceuticals position peaked at $253K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.